PUBLIC COMPANY
saveHORIZON
USupdated 6mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- GSK restructure will hit home, impacting 'limited' UK rolesFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 10h ago
- STAT+: Will the Treasury restrict U.S. investment in the Chinese biotech sector?Rumors are swirling that the Treasury Department this week is going to propose a rule that restricts U.S. investment in the Chinese biotech sector.stat · 6d ago
- Rudy Tanzi has long wanted to prevent Alzheimer's. He may be closeFor decades, Rudolph Tanzi has dreamt of a “little white pill” to prevent Alzheimer’s disease that would be so cheap and so safe, it could practically be added to tap water. Now, Tanzi is finally ...endpoints · 15d ago
- BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growthBristol Myers Squibb has reported phase 3 wins in a lung disease and a solid tumor, taking two steps on its path toward post-patent cliff growth.fiercebiotech · 16d ago
- Roivant, the 'inveterate drug hunters', enters commercial era with LisrayaCEO Matt Gline is juggling Roivant Sciences' first solo drug launch and several maturing programs as the hub-and-spoke company sets its sights on a massive turning point into commercial viability.biospace · 23d ago
- Bristol Myers trial revisions shake confidence in new class of fibrosis drugsA spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in testing of Bristol Myers’ admilparant — though it’s unclear whether the…biopharma_dive · 28d ago
- Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibodyAmgen has shed light on its phase 2 lupus win, revealing that its monoclonal antibody daxdilimab was tied to a 6-point reduction in disease severity at the lower dose.fiercebiotech · 28d ago
- No ‘Sunday scaries’: Claire Mazumdar on building Bicara—and knowing when to hand over the reinsStrange and bittersweet. That’s how Claire Mazumdar describes her plan to step down from the top spot at Bicara, a biotech she helped form, and head out on parental leave before transitioning into…biospace · 28d ago
- Opinion: STAT+: A moment of reckoning for preventive cardiology and the precision medicine revolution“The epidemiology and genetics of heart attack and stroke risk, for now, seem to have outpaced what more we can actually do about it,” writes cardiologist Vishal Khetpal.stat · 1mo ago
- Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren's studyAmgen is awaiting another Phase 3 readout for the investigational Sjögren's disease therapy, set for later this year. William Blair anticipates that at least two trials will be needed to support an…biospace · 1mo ago
comments(0)
5-min edit window · permanent after that